Uncategorized files

Showing below up to 50 results in range #58,801 to #58,850.

• 
  Tekamlo NDC 00780606.jpg 640 × 480; 20 KB
  
• 
  Tekturna03.jpg 551 × 416; 46 KB
  
• 
  Tekturna05.jpg 607 × 513; 58 KB
  
• 
  Tekturna06.jpg 745 × 247; 58 KB
  
• 
  Tekturna07.jpg 741 × 164; 44 KB
  
• 
  Tekturna08.jpg 740 × 157; 38 KB
  
• 
  Tekturna09.jpg 741 × 138; 30 KB
  
• 
  Tekturna10.jpg 887 × 264; 86 KB
  
• 
  Tekturna11.jpg 742 × 108; 29 KB
  
• 
  Tekturna12.jpg 196 × 178; 9 KB
  
• 
  Tekturna13.jpg 196 × 178; 9 KB
  
• 
  Tekturna HCT NDC 00780521.jpg 1,024 × 781; 138 KB
  
• 
  Tekturna HCT NDC 00780523.jpg 640 × 480; 85 KB
  
• 
  Tekturna NDC 00780485.jpg 1,024 × 781; 140 KB
  
• 
  Tekturna NDC 00780486.jpg 1,024 × 768; 589 KB
  
• 
  Telangectasia.jpg 248 × 231; 7 KB
  
• 
  Telangiectasia eye.jpg 699 × 512; 35 KB
  
• 
  Telaprevir 1.jpg 475 × 175; 14 KB
  
• 
  Telaprevir 10.png 1,112 × 318; 31 KB
  
• 
  Telaprevir 11.png 834 × 348; 24 KB
  
• 
  Telaprevir 2.jpg 1,043 × 338; 132 KB
  
• 
  Telaprevir 3.jpg 1,041 × 296; 76 KB
  
• 
  Telaprevir 4-vert.jpg 1,032 × 2,477; 1.2 MB
  
• 
  Telaprevir 5.jpg 1,042 × 279; 82 KB
  
• 
  Telaprevir 6.jpg 1,039 × 89; 29 KB
  
• 
  Telaprevir 7.png 793 × 593; 335 KB
  
• 
  Telaprevir 8.png 694 × 596; 373 KB
  
• 
  Telaprevir 9.jpg 1,111 × 238; 67 KB
  
• 
  Telavancin.png 1,459 × 1,109; 39 KB
  
• 
  Telavancin hydrochloride 250 mg.png 634 × 650; 328 KB
  
• 
  Telavancin hydrochloride 750 mg.png 634 × 711; 333 KB
  
• 
  Telavancin hydrochloride All-Cause Mortality at Day 28 in Patients with at least One Baseline Gram-Positive Pathogen.png 627 × 563; 74 KB
  
• 
  Telavancin hydrochloride Baseline Infection Types in Patients in cSSSI.png 624 × 337; 35 KB
  
• 
  Telavancin hydrochloride Clinical Cure Rates at the Test-of-Cure for the Most Common Pathogens in cSSSI Trials 1 and 2.png 620 × 523; 67 KB
  
• 
  Telavancin hydrochloride Clinical Cure at Test-of-Cure in cSSSI Trials 1 and 2.png 622 × 316; 40 KB
  
• 
  Telavancin hydrochloride Clinical Response Rates in Trials 1 and 2 – AT and CE Populations.png 620 × 413; 47 KB
  
• 
  Telavancin hydrochloride Coagulation Tests Affected and Unaffected by Telavancin.png 613 × 262; 33 KB
  
• 
  Telavancin hydrochloride Complicated Skin and Skin Structure Infections.png 628 × 570; 51 KB
  
• 
  Telavancin hydrochloride Decreased Clinical Response in Patients with cSSSI and Pre-existing Renal Impairment.png 634 × 213; 21 KB
  
• 
  Telavancin hydrochloride FDA package label.png 624 × 1,909; 170 KB
  
• 
  Telavancin hydrochloride HABP-VABP.png 624 × 422; 53 KB
  
• 
  Telavancin hydrochloride HABP-VABP adverse reactions.png 618 × 221; 24 KB
  
• 
  Telavancin hydrochloride chemical structure.png 298 × 243; 29 KB
  
• 
  Telavancin hydrochloride pharmacodynamics.png 619 × 331; 34 KB
  
• 
  Telavancin hydrochloride pharmacokinetics.png 629 × 570; 48 KB
  
• 
  Telavancin hydrochloride structure.png 366 × 159; 16 KB
  
• 
  Telbivudine00.png 220 × 217; 5 KB
  
• 
  Telbivudine01.png 607 × 262; 29 KB
  
• 
  Telbivudine02.png 607 × 895; 61 KB
  
• 
  Telbivudine03.png 609 × 532; 54 KB